Results 41 to 50 of about 23,420 (253)

Early markers of phenotypic heterogeneity in the induced model of systemic lupus erythematosus

Бюллетень сибирской медицины, 2018
The study aimed at evaluating the predisposition for development of different variants of SLE based on an inflammatory response in intact mice.Materials and methods.
O. P. Kolesnikova, E. V. Goiman, E. D. Gavrilova, E. N. Demchenko, V. A. Kozlov   +4 more
doaj   +1 more source

Die Bedeutung von cfDNA im 24h-Urin beim Multiplen Myelom

, 2023
Mit dieser Studie wurde untersucht, inwiefern circulating-free-DNA (cfDNA) im 24h-Urin von Patienten mit Multiplem Myelom (MM) ein möglicher zukünftiger Parameter in liquid biopsies darstellen könnte. Hierfür wurden Urin-, Blut- und Knochenmarkproben von
Neuse, C.J. (Carl)
core   +1 more source

Cell-free DNA in sports medicine: implications for clinical laboratory medicine

Journal of Laboratory Medicine, 2022
Physical activity can have a strong impact on the concentration of several promising candidate biomarkers, including cell-free DNA (cfDNA).
Neuberger Elmo W.I., Simon Perikles
doaj   +1 more source

Influence of preanalytical variables on the quality of cell-free DNA. Biobanking of cell-free DNA material

Кардиоваскулярная терапия и профилактика, 2022
The search for early disease markers and the development of diagnostic systems has recently been expanding within genomics. Genomic deoxyribonucleic acid (DNA), cell-free DNA (cfDNA) and microbiome DNA obtained from different types of samples (tissues ...
V. A. Kondratskaya, M. S. Pokrovskaya, Yu. V. Doludin, A. L. Borisova, A. S. Limonova, А. N. Meshkov, O. M. Drapkina   +6 more
doaj   +1 more source

Liquid biopsy in CNS tumors: Current status & future perspectives

Indian Journal of Pathology and Microbiology, 2022
Precise classification of central nervous system (CNS) malignancies is vital for the treatment and prognostication. Identification of noninvasive markers can be of importance to guide treatment decisions and in monitoring treatment response.
Nuzhat Husain, Adil Husain, Sridhar Mishra, Pallavi Srivastava   +3 more
doaj   +1 more source

Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients

Cancer Research, Statistics, and Treatment, 2019
Background: Outcomes based on liquid biopsy in poor performance, older, biopsy-ineligible advanced non-small cell lung cancer (NSCLC) patients are unknown.
Avinash Pandey, Sarjana Dutt, Anjana Singh, Amit Kumar, Shivkant Singh   +4 more
doaj   +1 more source

Urine-Based Cell-Free DNA Tests in Urothelial Cancer: Additional Value for Clinical Decision-Making?

Société Internationale d’Urologie Journal, 2023
None.
Lars Dyrskjøt
doaj   +1 more source

Astaxanthin/Tumor-fractions-cfDNA: First release

, 2022
This is the first release and will be ...
Astaxanthin
core   +1 more source

DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients

Epigenetics, 2020
Identification of cancer-specific methylation of DNA released by tumours can be used for non-invasive diagnostics and monitoring. We previously reported in silico identification of DNA methylation loci specifically hypermethylated in common human cancers
Lukas Vrba, Marc M. Oshiro, Samuel S. Kim, Linda L. Garland, Crystal Placencia, Daruka Mahadevan, Mark A. Nelson, Bernard W. Futscher   +7 more
doaj   +1 more source

Evaluating cfDNA Workflows and Applications

, 2023
Founded in 2007, Fate Therapeutics' mission has been to make "better cells for better therapies".1 Fate Therapeutics is developing off-the-shelf, genetically engineered, induced pluripotent stem cell (iPSC) derived immune-cell therapies for the treatment
Steven Castro
core